Literature DB >> 294108

Anti-androgen TSAA-291. V. Effects of the anti-androgen TSAA-291 on the androgen-receptor complex formation from [3H]testosterone in rat ventral prostates.

K Sudo, K Yoshida, Y Kimura, R Nakayama.   

Abstract

Intramuscular administration of a new steroidal anti-androgen, TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one), in doses of 0.05, 0.5 and 5 mg/kg body weight reduced the in vivo uptake of [3H]testosterone by the ventral prostate of castrated rats of 78, 59 and 37% of the control level, respectively. Analysis on subcellular fractions of the prostate by gel-filtration and sucrose density-gradient centrifugation followed by thin layer chromatographic identification of testosterone metabolites revealed that 5 alpha-dihydrotestosterone (5 alpha-DHT) which was found to be largely bound to macromolecules in the cytosol and nucleus was the predominant metabolite even in the presence of the anti-androgen, and radioactivities corresponding to the 5 alpha-DHT-macromolecular complexes were decreased by the anti-androgen. TSAA-291 also inhibited the in vitro formation of the 5 alpha-DHT-macromolecular complexes in both cytosol and nucleus from minced prostates incubated with [3H]testosterone. The importance of the findings is discussed in connection with the mode of anti-androgenic action of TSAA-291 in terms of the interaction with the androgen receptor.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 294108     DOI: 10.1530/acta.0.092s067

Source DB:  PubMed          Journal:  Acta Endocrinol Suppl (Copenh)        ISSN: 0300-9750


  2 in total

1.  Antiandrogenic treatment of benign prostatic hyperplasia: a placebo controlled trial.

Authors:  P Ostri; R Swartz; H H Meyhoff; J H Petersen; G Lindgård; C Frimodt-Møller; T Andersson; M S Nielsen
Journal:  Urol Res       Date:  1989

2.  Study of the effect of an anti-androgen (oxendolone) on experimentally induced canine prostatic hyperplasia. I. Morphological analysis.

Authors:  K Okada; K Oishi; O Yoshida; K Sudo; M Kawase; R Nakayama
Journal:  Urol Res       Date:  1988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.